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قصور كظر ثانوي نتيجة اعطاء دواء الريتونافري مع خباخ فلوتيكاسون بروبيونات
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abstract: Ritonavir is a powerful inhibitor of the cytochrome P450 3A4 (CYP3A4) isoenzyme. It is used as a 
pharmaceutical enhancer in the management of HIV-positive patients. However, when co-administered with other 
drugs that are metabolised via the CYP3A4 pathway, ritonavir can potentially cause serious drug-drug interactions. 
Inhaled fluticasone propionate, which is used to treat asthma and chronic obstructive airway disease, is particularly 
prone to such interactions due to its physiological attributes. We report a HIV-positive 48-year-old male patient 
who presented to Al Nahdha Hospital, Muscat, Oman, in 2012 with weight loss, generalised weakness and fatigue 
and diagnosed with secondary adrenal insufficiency as a result of concomitant ritonavir and inhaled fluticasone.
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امللخ�ص: يعترب الريتونافري مثبط قوي لالأيزواأنزمي �سيتوكروم )P450 3A4 )CYP3A4. والذي يتم ا�ستخدامه كعالج للمر�سى امل�سابني 
بفريو�ص العوز املناعي املكت�سب. اأال اأنه عند ا�ستخدامه مع اأدوية اأخرى تتحلل عن طريق نف�ص عمليات االأي�ص التي يتحلل بها ال�سيتوكروم 
CYP3A4، حتدث اّثار جانبية نتيجة هذه التفاعالت الدوائية. و من هذه االأدوية  بخاخ فلوتيكا�سون بروبيونيت، الذي ي�ستخدم لعالج 
مر�سى الربو ومر�ص جمرى الهواء االإن�سدادي املزمن، والذي يكون اأكرث عر�سة ب�سكل خا�ص لهذه التفاعالت ب�سبب خ�سائ�سه الف�سيولوجية 
. قمنا بت�سجيل حالة مري�ص بفريو�ص العوز املناعي املكت�سب والذي يبلغ من العمر 48 عام وح�رص مل�ست�سفى النه�سة مبحافظة م�سقط يف 
�سلطنة عمان يف عام 2012، وكان ي�ستكي من فقدان يف الوزن، اإعياء وخمول عام، ومت ت�سخي�سه بق�سور الكظر الثانوي نتيجة م�ساحبة 
اأدوية الريتونافري وبخاخ فلوتيكا�سون بروبيونات.
الكلمات املفتاحية: فريو�ص العوز املناعي املكت�سب؛ الريتونافري؛ فلوتيكا�سون؛ تفاعالت اأدوية؛ ق�سور الكظر؛ حالة مر�سية؛ عمان.
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Fluticasone propionate is an inhaled steroid 
used to manage chronic obstructive airway disease 
and asthma and is a substrate of the CYP3A4 
enzyme similar to beclomethasone, budesonide and 
triamcinolone.5 However, fluticasone propionate is 
more likely to interact with CYP3A4 inhibitors due 
to its longer half-life, higher glucocorticoid receptor-
binding affinity, greater lipophilicity and larger volume 
distribution.5 A pharmacokinetic study of healthy 
volunteers found that ritonavir increased the area 
under the curve of serum fluticasone by 350-fold.6 This 
case report describes the development of secondary 
adrenal insufficiency in an HIV-positive patient as a 
result of the concomitant administration of ritonavir 
and inhaled fluticasone propionate.
The use of highly-active antiretroviral therapy (HAART) has revolutionised the prognosis of HIV-infected patients and 
ensured that the infection remains a treatable chronic 
condition. With prompt diagnosis and treatment, HIV- 
infected individuals now have a life expectancy 
similar to that of the general population.1 Ritonavir, 
a powerful inhibitor of the cytochrome P 450 3A4 
(CYP3A4) isoenzyme, is often prescribed once daily 
in small doses to HIV patients as a pharmacokinetic 
enhancer of protease inhibitors.2 This allows the use 
of fewer protease inhibitor tablets, hence improving 
patient compliance and increasing the potency of 
HAART.3 However, harmful interactions can occur 
when ritonavir is co-administered with other drugs 
that are metabolised via the CYP3A4 pathway, such as 
corticosteroids, macrolides and statins.3,4 
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A 48-year-old man presented to the HIV clinic of Al 
Nahdha Hospital, Muscat, Oman, in 2012 for a routine 
check-up. He had initially been diagnosed with an 
asymptomatic HIV infection in 1999 with a baseline 
cluster of differentiation (CD)4 count of >200 cells/mL3. 
At the time of diagnosis, his only comorbidity was 
bronchial asthma. Subsequently, the patient had 
developed an atypical mycobacterial infection in 2008 
after which HAART was initiated in the form of 150 mg 
of lamivudine and 300 mg of zidovudine twice a day 
and 600 mg of efavirenz once a day. Six months later, 
due to virological failure, his medication regimen was 
changed to 400 mg of oral didanosine once a day and 
40 mg of oral stavudine and 800/100 mg of oral rito-
navir-boosted indinavir/ritonavir twice a day. This 
resulted in a satisfactory immunological response and 
complete viral load suppression. However, due to 
intolerance, these antiretroviral (ARV) drugs were 
again changed in 2010 to 150 mg of oral lamivudine, 
300 mg of oral abacavir and 400/100 mg of oral 
lopinavir/ritonavir twice a day. From 1999 until 2007, 
the patient also took 200 μg of inhaled salbutamol as 
required and 100 μg of inhaled beclomethasone twice 
a day for his asthma. In 2008, the beclomethasone 
was substituted for 250 μg of inhaled fluticasone 
propionate twice a day. 
At presentation, the patient reported a two-
month history of weight loss, generalised weakness 
and fatigue. His vital signs were normal apart from 
low blood pressure (90/60 mmHg). His examination 
results were unremarkable, with no signs of Cushing’s 
syndrome or lipodystrophy. Routine investigations, 
including a complete blood count and urea, electrolyte, 
liver function, thyroid function and lipid profile tests, 
were all within normal limits. His CD4 count was 425 
cells/mL3 and the HIV viral load was <20 copies/mL. 
At baseline, his morning serum cortisol levels were 
7 nmol/L (normal range: 200–550 nmol/L) on two 
occasions and his plasma adrenocorticotropic 
hormone (ACTH) level was 5.4 pg/mL (normal range: 
7–50 pg/mL). One hour after administrating 250 μg 
of synthetic ACTH, his cortisol level increased to 
71 nmol/L. Levels of other pituitary hormones, plasma 
sodium and potassium were within normal limits.
A diagnosis of secondary adrenal insufficiency 
was made. The administration of inhaled fluticasone 
propionate was immediately halted and the patient was 
instead prescribed 20 mg of oral hydrocortisone in two 
divided doses per day. Within four weeks, symptoms 
of weakness and fatigue had dramatically improved; 
moreover, the asthma symptoms did not worsen 
and the patient continued using 200 μg of inhaled 
salbutamol as required. Following the fluticasone 
withdrawal, basal cortisol levels were 136 nmol/L 
and 317 nmol/L at 8 and 11 months, respectively. 
His ACTH level was 43.1 pg/mL at 11 months. After 
a period of one year, the hydrocortisone dose was 
tapered successfully over a three month period. Finally, 
one month after the hydrocortisone was discontinued, 
the patient’s response to synthetic ACTH was normal. 
Table 1 shows the patient’s serial basal and stimulated 
cortisol levels and plasma ACTH levels over time.
Discussion
Previous research has indicated that the concomitant 
use of inhaled fluticasone propionate and ritonavir 
leads to the systemic accumulation of fluticasone, 
consequently causing iatrogenic Cushing’s syndrome 
and secondary adrenal insufficiency.7–14 In a recent 
literature review, Epperla et al. reported a total 
of 37 cases of iatrogenic Cushing’s syndrome and 
adrenal suppression as a result of concomitant use of 
fluticasone and ritonavir in which the time between 
co-administration and the development of symptoms 
ranged from two weeks to two years.7 Another review 
showed that it took between two weeks and 12 months 
for patients to experience a complete resolution of 
symptoms after either drug was discontinued.8 In the 
current case, the patient had low ACTH and morning 
cortisol levels and a subnormal response to synthetic 
ACTH. This confirmed the diagnosis of secondary 
adrenal insufficiency. Moreover, the recovery of 
the hypothalamic-pituitary-adrenal axis after the 
withdrawal of fluticasone propionate established the 
cause of the adrenal insufficiency to be a drug-drug 
interaction.
In the present case, the patient initially reported 
symptoms of adrenal suppression four years after the 
concurrent use of fluticasone propionate and ritonavir 
Table 1: Serial basal and stimulated cortisol and 
adrenocorticotropic hormone levels of a HIV-positive 













At presentation 7 71 5.4
1 month later 11 - -
8 months later 136 - -
11 months later 317 - 43.1
16 months later 390 880 -
ACTH = adrenocorticotropic hormone.
*One hour after the administration of 250 μg of synthetic ACTH.
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medications that are substrates of the CYP3A4 
isoenzyme. It is important that both HIV care 
providers and primary care physicians are aware of 
this risk to minimise the occurrence of such events.
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was initiated; however, it is difficult to ascertain when 
the symptoms first appeared. In addition, although the 
resolution of the symptoms of adrenal insufficiency 
occurred within four weeks of discontinuing fluticasone 
propionate and initiating hydrocortisone treatment, 
it took 11 months for the full recovery of function of 
the pituitary and adrenal glands. The replacement of 
lopinavir/ritonavir with another ARV drug which does 
not inhibit the CYP 3A4 pathway, such as raltegravir, 
would have been an alternative management strategy.15 
However, in view of the patient’s history of virological 
failure with non-nucleoside reverse transcriptase inhib- 
itor-based HAART, ritonavir-boosted protease inhib-
itors were continued to ensure control of the HIV 
infection. Fortunately, the patient’s asthma symptoms 
did not deteriorate after the withdrawal of fluticasone 
propionate and he did not require an inhaled steroid. 
Notably, no phenotypic changes indicative of Cushing’s 
syndrome were observed at the time of the initial 
diagnosis of adrenal insufficiency. The treating physician 
might have mistaken such features, namely central 
obesity and the presence of a dorsocervical fat pad, to 
be those of ARV-induced lipodystrophy.7,8
To the best of the authors’ knowledge, this is 
the first case of secondary adrenal insufficiency as a 
result of concomitant ritonavir and inhaled fluticasone 
propionate reported from the Middle East and North 
African region. The Joint United Nations Programme 
on HIV/AIDS has advocated for a treatment target of 
90% of all HIV-infected people to receive antiretroviral 
therapy (ART) by 2020; it is therefore likely that 
the use of ART in this region will increase as the 
deadline for this target approaches.16 This expansion 
of ART provision will require support and vigilance 
from both pharmacists and HIV physicians in order 
to avoid serious drug-drug interactions between 
ART—especially ritonavir—and the medications 
used to manage other comorbidities. Enhanced 
communication between HIV clinics and primary 
healthcare workers is highly recommended to help 
minimise the frequency of these events. Furthermore, 
where resources allow, the allocation of an HIV-
specialist pharmacist to HIV clinics would ensure that 
all drug prescriptions are monitored prior to being 
filled. If this is unfeasible, a more pragmatic approach 
would be to provide prescribers with a list of common 
drug-drug interactions and/or access to computerised 
software to enable drug-drug interaction screening. 
Conclusion
This case highlights the potential for serious drug-
drug interactions when prescribing a potent CYP3A4 
inhibitor (i.e. ritonavir) with other commonly-used 
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